Health care resource use and approaches to clinical management of advanced non-small cell lung cancer vary significantly in eight different countries. READ MORE
News
Health care resource use and approaches to clinical management of advanced non-small cell lung cancer vary significantly in eight different countries.
Specific ALK variants may be linked to the development of ALK resistance mutations and poor clinical outcomes in patients with non-small cell lung cancer.
A recent study examined whether the Lung Immune Prognostic Index was associated with resistance to immunotherapy in patients with advanced non-small cell lung cancer.
A plasma-based next-generation sequencing option allows for sensitive detection and monitoring of mutations in advanced non-small cell lung cancer.
Resources
The National Comprehensive Cancer Network modified their guidelines for both non-small cell lung cancer and lung cancer screening to reflect new staging designations and testing results.
